Earnings
Aryx Therapeutics 1Q Loss Widens On Revenue Drop
FREMONT, Calif. (AP) — Development-stage biotechnology company Aryx Therapeutics Inc. said Thursday its first-quarter loss widened slightly on lack of licensing revenue after ending a partnership.
The company lost $9.8 million, or 36 cents per share, compared with a loss of $9.5 million, or 54 cents per share, during the same period a year prior. It reported no revenue compared with just over $1 million a year earlier. Analysts polled by Thomson Reuters expected a loss of 50 cents per share on no revenue. In the prior year, the company had a technology licensing deal with Procter & Gamble. That partnership also ended in 2008. Meanwhile, lower costs helped offset the lack of revenue. Costs and expenses fell 11 percent to $9.4 million as the company completed a midstage study of budiodarone as an abnormal heart rhythm treatment. The company is also developing an anticoagulant agent, warfarin. Shares of Aryx rose 3 cents to $5 in morning trading.TheStreet Premium Services
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,454.83 | 1,317.82 | 2,837.53 | 17.45 |
Oil *
107.20
|
|
DOWN
74.92 |
DOWN
2.86 |
DOWN
1.85 |
DOWN
0.14 |
10 Yr
1.74%
SPDR Gold
152.68
|
|
-0.60%
|
-0.22%
|
-0.07%
|
-0.80%
|
Data delayed 20 minutes |
Connect with TheStreet